11 results about "Kidney Insufficiency" patented technology

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

The invention relates to the technical field of biomedical detection, and particularly discloses a marker composition for diagnosing Alzheimer's disease and application of the marker composition. The marker composition comprises p-tau217 and GFAP, and can realize accurate screening of the early stage and the clinical stage of the Alzheimer's disease. The invention also provides a diagnostic reagent by using the marker composition, the reagent adopts a biotin-streptavidin amplification principle, and the detection accuracy of the biomarker can be obviously improved; meanwhile, a kit is designed based on the reagent, the partition pore plate design is adopted, and the cross contamination probability is reduced by arranging an isolation groove with a hydrophobic material. Besides, the invention further provides a system with diagnosis and correction functions, interference of hemolysis and / or renal insufficiency on Alzheimer's disease diagnosis can be eliminated, and the problem that an existing Alzheimer's disease diagnosis technology is prone to missed diagnosis and misdiagnosis is effectively solved.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The invention relates to a heart failure risk prediction method and device, equipment and a medium. According to the method, clinical index data of a patient suffering from acute myocardial infarction are obtained, the clinical index data comprise the age, the diabetes disease condition, the hyperlipidemia disease condition, the renal insufficiency disease condition and the cerebral apoplexy disease condition, and an initial prediction model of the concurrent heart failure risk of the patient suffering from acute myocardial infarction is constructed; and obtaining an initial prediction model, training the initial prediction model to obtain a target prediction model, inputting the clinical index data into the target prediction model, and outputting a risk prediction value of the acute myocardial infarction patient concurrent with heart failure based on the target prediction model. By means of the method, conventional and easily-obtained clinical indexes can be used, it is not needed to wait for complex or expensive examination results, evaluation can be conducted immediately after a patient enters a hospital, subjective experience judgment is replaced with the model, quantitative risk values are output, and a basis is provided for clinical decision making.

This invention discloses a pharmaceutical composition containing cefoperazone sodium and tazobactam sodium for the treatment of renal insufficiency complicated with bacterial infection. The weight ratio of cefoperazone sodium to tazobactam sodium is 6:1. In the treatment of renal insufficiency complicated with bacterial infection, this composition effectively improves clinical efficacy while significantly reducing the incidence of adverse reactions, achieving a good balance between efficacy and safety. This invention also provides a pharmaceutical composition that effectively reduces the production of related substances, significantly improving the product quality of the 6:1 cefoperazone sodium and tazobactam sodium mixture, and further ensuring the stability of the drug during use, storage, and transportation.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for tonifying spleen and kidney, a medicine and a preparation method thereof. The traditional Chinese medicine composition aims to solve the problems of treating symptoms but not root causes of chronic renal insufficiency in the prior art, can effectively reduce key indexes (such as creatinine and urea nitrogen) of the renal insufficiency, can start from pathogenesis, has the effects of strengthening spleen and tonifying kidney to consolidate the root, dissolving turbidity and dredging collaterals to treat symptoms, and can avoid adverse reactions caused by long-term medication.

The invention discloses indometacin emulsifiable paste and a preparation method thereof, and aims to solve the problems that the existing oral indometacin is large in gastrointestinal irritation, and an external preparation is low in solubility, poor in transdermal permeability and insufficient in stability. The emulsifiable paste comprises the following components in parts by weight: an oil-phase matrix consisting of indometacin, dimethyl sulfoxide, liquid paraffin, white vaseline, octadecanol and hexadecanol, and a water-phase matrix consisting of lauryl sodium sulfate, urea and the like. The emulsifiable paste is high in indometacin solubility, excellent in transdermal efficiency, good in stability and free of gastrointestinal tract irritation, is suitable for the elderly, special crowds with hepatic and renal insufficiency and the like, and is suitable for industrialization and clinical application.

The invention discloses a small molecule compound for regulating and controlling an autophagy-lipid pathway and application of the small molecule compound to treatment of NAFLD, and relates to the technical field of medicines. The invention provides an NAFLD treatment strategy of lipophagy-mitochondrial autophagy dual-channel coordinated regulation for the first time, and the NAFLD treatment strategy is different from existing single-target (such as ACC and FXR) drugs; according to the compound, benzimidazole-piperazine is used as a parent nucleus, double-target regulation of mTOR / AMPK is achieved through substituent optimization, the structure is novel, and it is confirmed that no existing patent or literature report exists through compound structure retrieval (SciFinder); the compound can be used for whole course treatment of NAFLD, and is especially suitable for NAFLD patients with cardiovascular diseases or renal insufficiency and with existing drug taboo, and the range of treatment crowds is expanded.